Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.11
ABT's Cash to Debt is ranked lower than
64% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. ABT: 1.11 )
Ranked among companies with meaningful Cash to Debt only.
ABT' s 10-Year Cash to Debt Range
Min: 0.05  Med: 0.28 Max: 1.23
Current: 1.11
0.05
1.23
Equity to Asset 0.51
ABT's Equity to Asset is ranked lower than
69% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. ABT: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
ABT' s 10-Year Equity to Asset Range
Min: 0.37  Med: 0.44 Max: 0.59
Current: 0.51
0.37
0.59
Interest Coverage 17.33
ABT's Interest Coverage is ranked lower than
78% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. ABT: 17.33 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s 10-Year Interest Coverage Range
Min: 4.91  Med: 15.57 Max: 34.27
Current: 17.33
4.91
34.27
F-Score: 7
Z-Score: 3.89
M-Score: -2.55
WACC vs ROIC
10.63%
8.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 14.05
ABT's Operating margin (%) is ranked higher than
81% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. ABT: 14.05 )
Ranked among companies with meaningful Operating margin (%) only.
ABT' s 10-Year Operating margin (%) Range
Min: 8.81  Med: 19.41 Max: 24.91
Current: 14.05
8.81
24.91
Net-margin (%) 20.15
ABT's Net-margin (%) is ranked higher than
92% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. ABT: 20.15 )
Ranked among companies with meaningful Net-margin (%) only.
ABT' s 10-Year Net-margin (%) Range
Min: 7.64  Med: 16.49 Max: 27.74
Current: 20.15
7.64
27.74
ROE (%) 18.54
ABT's ROE (%) is ranked higher than
87% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. ABT: 18.54 )
Ranked among companies with meaningful ROE (%) only.
ABT' s 10-Year ROE (%) Range
Min: 9.78  Med: 23.47 Max: 43.42
Current: 18.54
9.78
43.42
ROA (%) 10.00
ABT's ROA (%) is ranked higher than
85% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. ABT: 10.00 )
Ranked among companies with meaningful ROA (%) only.
ABT' s 10-Year ROA (%) Range
Min: 4.68  Med: 11.65 Max: 18.73
Current: 10
4.68
18.73
ROC (Joel Greenblatt) (%) 28.52
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. ABT: 28.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.27  Med: 45.09 Max: 94.17
Current: 28.52
5.27
94.17
Revenue Growth (3Y)(%) -18.80
ABT's Revenue Growth (3Y)(%) is ranked lower than
85% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ABT: -18.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18.8  Med: 8.40 Max: 13.7
Current: -18.8
-18.8
13.7
EBITDA Growth (3Y)(%) -21.00
ABT's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. ABT: -21.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30  Med: 7.50 Max: 31.5
Current: -21
-30
31.5
EPS Growth (3Y)(%) -28.20
ABT's EPS Growth (3Y)(%) is ranked lower than
79% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. ABT: -28.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABT' s 10-Year EPS Growth (3Y)(%) Range
Min: -54  Med: 4.60 Max: 48.8
Current: -28.2
-54
48.8
» ABT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ABT Guru Trades in Q2 2014

First Eagle Investment 1,665,688 sh (New)
Paul Tudor Jones 25,430 sh (New)
Jim Simons 1,503,700 sh (New)
Ken Fisher 18,027 sh (+106.12%)
Diamond Hill Capital 6,422,284 sh (+7.31%)
Bill Frels 368,808 sh (+7.25%)
Richard Pzena 7,197,691 sh (+3.80%)
Ray Dalio 17,700 sh (+2.91%)
John Buckingham 89,447 sh (+1.32%)
PRIMECAP Management 17,127,063 sh (+0.23%)
Louis Moore Bacon 10,998 sh (unchged)
Robert Olstein 182,000 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Tom Russo 86,503 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Dodge & Cox 36,898 sh (-0.14%)
Mason Hawkins 13,687,877 sh (-0.43%)
Pioneer Investments 1,990,174 sh (-0.64%)
Jeff Auxier 79,671 sh (-1.02%)
Murray Stahl 34,303 sh (-1.72%)
Mario Gabelli 160,707 sh (-4.62%)
George Soros 932,181 sh (-23.73%)
Jeremy Grantham 11,956,508 sh (-26.92%)
» More
Q3 2014

ABT Guru Trades in Q3 2014

Steven Cohen 200,000 sh (New)
Diamond Hill Capital 7,624,383 sh (+18.72%)
Dodge & Cox 39,628 sh (+7.40%)
Richard Pzena 7,287,523 sh (+1.25%)
John Buckingham 89,801 sh (+0.40%)
Westport Asset Management 200,000 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Tom Russo 86,503 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Robert Olstein 182,000 sh (unchged)
Pioneer Investments 1,989,506 sh (unchged)
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
PRIMECAP Management 17,089,257 sh (-0.22%)
Jeff Auxier 79,371 sh (-0.38%)
Bill Frels 359,970 sh (-2.40%)
Mason Hawkins 12,483,566 sh (-8.80%)
First Eagle Investment 1,426,919 sh (-14.33%)
George Soros 797,181 sh (-14.48%)
Murray Stahl 29,303 sh (-14.58%)
Jeremy Grantham 10,155,603 sh (-15.06%)
Ken Fisher 11,261 sh (-37.53%)
Mario Gabelli 98,937 sh (-38.44%)
Paul Tudor Jones 8,170 sh (-67.87%)
Jim Simons 144,983 sh (-90.36%)
» More
Q4 2014

ABT Guru Trades in Q4 2014

Ray Dalio 45,000 sh (New)
Jim Simons 859,200 sh (+492.62%)
Ken Fisher 13,828 sh (+22.80%)
Diamond Hill Capital 8,070,717 sh (+5.85%)
PRIMECAP Management 17,638,084 sh (+3.21%)
John Buckingham 90,882 sh (+1.20%)
Robert Bruce 230,915 sh (+0.70%)
Paul Tudor Jones 8,209 sh (+0.48%)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Steven Cohen Sold Out
Jeff Auxier 78,871 sh (-0.63%)
Bill Frels 356,819 sh (-0.88%)
Tom Russo 85,400 sh (-1.28%)
Pioneer Investments 1,959,061 sh (-1.53%)
Robert Olstein 179,000 sh (-1.65%)
Richard Pzena 6,860,439 sh (-5.86%)
Dodge & Cox 37,068 sh (-6.46%)
Jeremy Grantham 9,110,222 sh (-10.29%)
First Eagle Investment 1,250,956 sh (-12.33%)
George Soros 602,181 sh (-24.46%)
Murray Stahl 21,473 sh (-26.72%)
Mason Hawkins 8,977,941 sh (-28.08%)
Mario Gabelli 65,337 sh (-33.96%)
» More
Q1 2015

ABT Guru Trades in Q1 2015

Joel Greenblatt 41,573 sh (New)
First Eagle Investment 5,142,802 sh (+311.11%)
Jeremy Grantham 10,727,819 sh (+17.76%)
Paul Tudor Jones 9,300 sh (+13.29%)
Pioneer Investments 1,995,930 sh (+1.88%)
PRIMECAP Management 17,765,299 sh (+0.72%)
Diamond Hill Capital 8,106,888 sh (+0.45%)
John Buckingham 90,906 sh (+0.03%)
Robert Olstein 179,000 sh (unchged)
George Soros 602,181 sh (unchged)
Tom Russo 85,400 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Ray Dalio Sold Out
Mason Hawkins Sold Out
Mario Gabelli 65,287 sh (-0.08%)
Bill Frels 353,724 sh (-0.87%)
Ken Fisher 13,095 sh (-5.30%)
Richard Pzena 6,373,745 sh (-7.09%)
Murray Stahl 18,603 sh (-13.37%)
Dodge & Cox 32,068 sh (-13.49%)
Jim Simons 412,300 sh (-52.01%)
Jeff Auxier 35,671 sh (-54.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Abbott Laboratories

Mason Hawkins Comments on Abbott Laboratories - May 28, 2015

Abbott (ABT), a global healthcare company, reached our appraisal, resulting in a 120% return over our 4-year holding period. We are extremely appreciative of the value that CEO Miles White built for shareholders during our ownership.

From Mason Hawkins (Trades, Portfolio)’ Longleaf Partners Fund Q1 2015 Management Discussion.

Check out Mason Hawkins latest stock trades

Lountzis Asset Management Comments on Abbott Laboratories - Mar 21, 2014

ABBOTT LABORATORIES (ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products.



On January 1, 2013, Abbott consummated the separation of its research based pharmaceuticals business and distributed 100% of the outstanding shares of common stock of AbbVie to the holders of record of Abbott common shares that were issued and outstanding on December 12, 2012. Each Abbot shareholder received one share of AbbVie common stock for every share of Abbot common stock held. The Abbott shareholder also received cash in lieu of any fractional share of AbbVie common stock resulting from the distribution.



Abbott common shares now trade under ticker symbol "ABT" and shares of AbbVie common stock trade under ticker symbol "ABBV". The new Abbott is a diversified global healthcare company with several leading franchises. In 2012, the company generated sales of $21.5 billion from these four diverse business units: nutritionals 30%, medical products 25%, established pharmaceuticals 24% and diagnostics 20%.



Abbott has leading market share positions in several businesses including the number one market share in:



1. Worldwide Adult Nutrition and U.S. Pediatric Nutrition



2. Amino Acid Immunoassay Diagnostics and Blood Screening



3. Drug Eluting Stents and for



4. Lasik



Furthermore, Abbott, in addition to a broad portfolio of products and services, is geographically diverse with 29% of sales in the U.S., 30% in other developed markets and 40% in the more rapidly growing emerging markets. The current Chairman and CEO, Miles D. White, will continue in these positions for the new Abbott, focused upon several initiatives including expanding the company’s products into new geographic markets, developing new technologies and focusing on accelerating margin expansion and improving free cash flow.



The new Abbott generated 2013 revenue through its four segments of $21.9 billion with earnings per share of $2.01. We continue to hold the new Abbott and believe its product and geographic diversity, combined with its leadership positions in several areas, will enable the company to continue to grow and prosper.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Diamond Hill Capital Comments on Abbott Laboratories - Jan 15, 2014

Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Abbott Laboratories

Mason Hawkins Comments on Abbott Laboratories
Abbott (ABT), a global healthcare company, reached our appraisal, resulting in a 120% return over our 4-year holding period. We are extremely appreciative of the value that CEO Miles White built for shareholders during our ownership. Read more...
Diamond Hill Adds Two Companies to Portfolio in Third Quarter
At its web site, Diamond Hill Capital (Trades, Portfolio) Management calls itself “an independent investment management firm headquartered in Columbus, Ohio.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.90
ABT's P/E(ttm) is ranked higher than
74% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 27.60 vs. ABT: 17.90 )
Ranked among companies with meaningful P/E(ttm) only.
ABT' s 10-Year P/E(ttm) Range
Min: 5.76  Med: 10.03 Max: 34.88
Current: 17.9
5.76
34.88
Forward P/E 20.92
ABT's Forward P/E is ranked higher than
55% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 22.17 vs. ABT: 20.92 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 36.30
ABT's PE(NRI) is ranked lower than
64% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 27.80 vs. ABT: 36.30 )
Ranked among companies with meaningful PE(NRI) only.
ABT' s 10-Year PE(NRI) Range
Min: 5.76  Med: 10.68 Max: 97.44
Current: 36.3
5.76
97.44
P/B 3.41
ABT's P/B is ranked lower than
54% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.13 vs. ABT: 3.41 )
Ranked among companies with meaningful P/B only.
ABT' s 10-Year P/B Range
Min: 1.39  Med: 2.23 Max: 3.45
Current: 3.41
1.39
3.45
P/S 3.60
ABT's P/S is ranked lower than
55% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.19 vs. ABT: 3.60 )
Ranked among companies with meaningful P/S only.
ABT' s 10-Year P/S Range
Min: 0.96  Med: 1.59 Max: 3.64
Current: 3.6
0.96
3.64
PFCF 32.94
ABT's PFCF is ranked lower than
55% of the 116 Companies
in the Global Medical Devices industry.

( Industry Median: 31.45 vs. ABT: 32.94 )
Ranked among companies with meaningful PFCF only.
ABT' s 10-Year PFCF Range
Min: 4.38  Med: 8.75 Max: 33.31
Current: 32.94
4.38
33.31
POCF 22.56
ABT's POCF is ranked lower than
53% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. ABT: 22.56 )
Ranked among companies with meaningful POCF only.
ABT' s 10-Year POCF Range
Min: 3.81  Med: 6.55 Max: 22.82
Current: 22.56
3.81
22.82
EV-to-EBIT 23.74
ABT's EV-to-EBIT is ranked lower than
55% of the 163 Companies
in the Global Medical Devices industry.

( Industry Median: 22.11 vs. ABT: 23.74 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s 10-Year EV-to-EBIT Range
Min: 6.7  Med: 10.30 Max: 32.4
Current: 23.74
6.7
32.4
Shiller P/E 16.57
ABT's Shiller P/E is ranked higher than
85% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 30.32 vs. ABT: 16.57 )
Ranked among companies with meaningful Shiller P/E only.
ABT' s 10-Year Shiller P/E Range
Min: 8.15  Med: 11.27 Max: 16.77
Current: 16.57
8.15
16.77
Current Ratio 2.17
ABT's Current Ratio is ranked lower than
58% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. ABT: 2.17 )
Ranked among companies with meaningful Current Ratio only.
ABT' s 10-Year Current Ratio Range
Min: 0.75  Med: 1.37 Max: 2.36
Current: 2.17
0.75
2.36
Quick Ratio 1.89
ABT's Quick Ratio is ranked lower than
53% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ABT: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s 10-Year Quick Ratio Range
Min: 0.55  Med: 1.07 Max: 2.07
Current: 1.89
0.55
2.07
Days Inventory 107.39
ABT's Days Inventory is ranked higher than
63% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.50 vs. ABT: 107.39 )
Ranked among companies with meaningful Days Inventory only.
ABT' s 10-Year Days Inventory Range
Min: 76.02  Med: 103.07 Max: 131.57
Current: 107.39
76.02
131.57
Days Sales Outstanding 60.96
ABT's Days Sales Outstanding is ranked higher than
62% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. ABT: 60.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s 10-Year Days Sales Outstanding Range
Min: 54.72  Med: 68.06 Max: 129.28
Current: 60.96
54.72
129.28

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.86
ABT's Dividend Yield is ranked higher than
69% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. ABT: 1.86 )
Ranked among companies with meaningful Dividend Yield only.
ABT' s 10-Year Dividend Yield Range
Min: 1.41  Med: 5.12 Max: 7.9
Current: 1.86
1.41
7.9
Dividend Payout 0.67
ABT's Dividend Payout is ranked higher than
87% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 0.38 vs. ABT: 0.67 )
Ranked among companies with meaningful Dividend Payout only.
ABT' s 10-Year Dividend Payout Range
Min: 0.16  Med: 0.46 Max: 2.53
Current: 0.67
0.16
2.53
Dividend growth (3y) -22.40
ABT's Dividend growth (3y) is ranked lower than
83% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ABT: -22.40 )
Ranked among companies with meaningful Dividend growth (3y) only.
ABT' s 10-Year Dividend growth (3y) Range
Min: -31.2  Med: 9.40 Max: 12.6
Current: -22.4
-31.2
12.6
Yield on cost (5-Year) 0.77
ABT's Yield on cost (5-Year) is ranked lower than
76% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 1.58 vs. ABT: 0.77 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABT' s 10-Year Yield on cost (5-Year) Range
Min: 0.59  Med: 2.13 Max: 3.28
Current: 0.77
0.59
3.28
Share Buyback Rate 0.90
ABT's Share Buyback Rate is ranked higher than
86% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. ABT: 0.90 )
Ranked among companies with meaningful Share Buyback Rate only.
ABT' s 10-Year Share Buyback Rate Range
Min: 0.9  Med: 0.10 Max: -0.8
Current: 0.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.35
ABT's Price/Tangible Book is ranked lower than
82% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.53 vs. ABT: 12.35 )
Ranked among companies with meaningful Price/Tangible Book only.
ABT' s 10-Year Price/Tangible Book Range
Min: 3.1  Med: 7.88 Max: 427.6
Current: 12.35
3.1
427.6
Price/Projected FCF 1.07
ABT's Price/Projected FCF is ranked higher than
82% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ABT: 1.07 )
Ranked among companies with meaningful Price/Projected FCF only.
ABT' s 10-Year Price/Projected FCF Range
Min: 0.36  Med: 0.79 Max: 1.93
Current: 1.07
0.36
1.93
Price/Median PS Value 2.38
ABT's Price/Median PS Value is ranked lower than
89% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. ABT: 2.38 )
Ranked among companies with meaningful Price/Median PS Value only.
ABT' s 10-Year Price/Median PS Value Range
Min: 0.66  Med: 1.12 Max: 2.23
Current: 2.38
0.66
2.23
Price/Graham Number 4.46
ABT's Price/Graham Number is ranked lower than
75% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. ABT: 4.46 )
Ranked among companies with meaningful Price/Graham Number only.
ABT' s 10-Year Price/Graham Number Range
Min: 1.17  Med: 2.27 Max: 20.52
Current: 4.46
1.17
20.52
Earnings Yield (Greenblatt) (%) 4.20
ABT's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. ABT: 4.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.1  Med: 9.70 Max: 15
Current: 4.2
3.1
15
Forward Rate of Return (Yacktman) (%) -14.57
ABT's Forward Rate of Return (Yacktman) (%) is ranked lower than
88% of the 99 Companies
in the Global Medical Devices industry.

( Industry Median: 4.13 vs. ABT: -14.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -11.2  Med: 16.70 Max: 33.2
Current: -14.57
-11.2
33.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:ABT.Argentina, ABL.Germany, ABT.Chile, ABTT34.Brazil, ABT.Mexico, ABT.Switzerland, ABT.UK,
Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally. Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells coronary, endovascular, structural heart, vessel closure and other medical device products.
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Mason Hawkins Comments on Abbott Laboratories May 28 2015 
Endo International Posts Upbeat Q1 Results May 13 2015 
How Much Money Will You Need To Retire? Mar 31 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
What Could Be The Major Highlights In AbbVie’s Upcoming Earnings Call? Jan 29 2015 
Feeling Good With This Med Company Jan 20 2015 
Diamond Hill Adds Two Companies to Portfolio in Third Quarter Dec 11 2014 
Boston Scientific Lost the First Place in Innovation Dec 11 2014 

More From Other Websites
These stocks win in 2nd half Jul 01 2015
Abbott Hosts Conference Call for Second-Quarter Earnings Jul 01 2015
Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog Jun 30 2015
Activist investors love spin-offs. Here’s why you should, too Jun 29 2015
Easier Blood-Sugar Monitoring for Diabetics Jun 28 2015
5 Trade Ideas for Monday: Abbott Labs, Cognex, Lazard, Northern Trust & Tractor Supply Jun 28 2015
3 Healthcare Stocks For A Growing Global Middle Class Jun 22 2015
Mylan Inks Deal with Pulmatrix for Respiratory Disease Drug - Analyst Blog Jun 17 2015
Abbott Backs Mylan and Its Strategy to Buy Perrigo Jun 16 2015
Big shareholder backs drugmaker Mylan's growth strategy Jun 16 2015
Big shareholder backs drugmaker Mylan's growth strategy Jun 16 2015
Stocks End Near Highs; Perrigo Rebounds On Mylan Deal Jun 16 2015
Deal talk drives US stocks to modest gains Jun 16 2015
Deal talk drives US stocks to modest gains Jun 16 2015
How An Inversion Is Paying Off Twice In Mylan's Fight Against Teva Pharmaceutical Jun 16 2015
Mylan's largest shareholder Abbott Laboratories backs in Perrigo bid Jun 16 2015
Abbott to Vote in Favor of Mylan's Perrigo Deal Jun 16 2015
Abbott to vote for Mylan's acquisition of Perrigo Jun 16 2015
Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction Jun 16 2015
Abbott Will Back Mylan’s Perrigo Bid Using 14.5% Share Stake Jun 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK